Literature DB >> 16085334

Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension?

Giovanni Sansoè1, Manuela Aragno, Raffaella Mastrocola, Francesca Restivo, Giulio Mengozzi, Antonina Smedile, Floriano Rosina, Oliviero Danni, Maurizio Parola, Mario Rizzetto.   

Abstract

BACKGROUND/AIMS: In liver cirrhosis atrial natriuretic peptide (ANP) decreases portal vascular resistance and tributary flow. The enzyme neutral endopeptidase (NEP) degrades ANP and bradykinin and generates endothelin-1 from big-endothelin. We determined the effects of NEP inhibition by candoxatrilat on hormonal status, liver function and arterial and portal pressures in rats with CCl4-induced cirrhosis.
METHODS: Two groups of seven control rats received 1 ml 5% glucose solution alone or containing 10 mg/kg candoxatrilat; three groups of 10 ascitic cirrhotic rats received placebo, 5 or 10 mg/kg candoxatrilat. NEP protein concentration and immunostaining were analyzed in normal and cirrhotic livers.
RESULTS: In cirrhotic rats 10 mg/kg candoxatrilat significantly increased steady-state indocyanine green clearance (a parameter reflecting liver plasma flow) (P<0.01), decreased portal pressure (P<0.01), had no effect on arterial pressure and plasma renin activity but increased ANP plasma levels (P<0.05) and urinary excretions (P<0.01) of ANP and cGMP. In the cytosol fraction of rat cirrhotic livers a 280% increase in NEP content was found (P<0.01), chiefly localized in desmin-positive myofibroblast-like cells of fibrous septa.
CONCLUSIONS: Candoxatrilat has few effects on systemic hemodynamics and hormonal status; its portal hypotensive action depends on effects exerted on intrahepatic vascular resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16085334     DOI: 10.1016/j.jhep.2005.04.017

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  7 in total

1.  Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells.

Authors:  Erica Novo; Stefania Cannito; Elena Zamara; Lorenzo Valfrè di Bonzo; Alessandra Caligiuri; Carlo Cravanzola; Alessandra Compagnone; Sebastiano Colombatto; Fabio Marra; Massimo Pinzani; Maurizio Parola
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

2.  Dual endothelin-converting enzyme/neutral endopeptidase blockade in rats with D-galactosamine-induced liver failure.

Authors:  Berthold Hocher; S Heiden; K von Websky; J Rahnenführe; P Kalk; T Pfab
Journal:  Eur J Med Res       Date:  2011-06-21       Impact factor: 2.175

3.  Role of Chymase in the Development of Liver Cirrhosis and Its Complications: Experimental and Human Data.

Authors:  Giovanni Sansoè; Manuela Aragno; Raffaella Mastrocola; Giulio Mengozzi; Erica Novo; Maurizio Parola
Journal:  PLoS One       Date:  2016-09-16       Impact factor: 3.240

4.  Dual Angiotensin Receptor and Neprilysin Inhibitor Ameliorates Portal Hypertension in Portal Hypertensive Rats.

Authors:  Shao-Jung Hsu; Hui-Chun Huang; Chiao-Lin Chuang; Ching-Chih Chang; Ming-Chih Hou; Fa-Yauh Lee; Shou-Dong Lee
Journal:  Pharmaceutics       Date:  2020-04-02       Impact factor: 6.321

5.  Plasma Neprilysin Displays No Relevant Association With Neurohumoral Activation in Chronic HFrEF.

Authors:  Suriya Prausmüller; Henrike Arfsten; Georg Spinka; Claudia Freitag; Philipp E Bartko; Georg Goliasch; Guido Strunk; Noemi Pavo; Martin Hülsmann
Journal:  J Am Heart Assoc       Date:  2020-05-19       Impact factor: 5.501

Review 6.  COVID-19 and Liver Cirrhosis: Focus on the Nonclassical Renin-Angiotensin System and Implications for Therapy.

Authors:  Giovanni Sansoè; Manuela Aragno; Florence Wong
Journal:  Hepatology       Date:  2021-07-26       Impact factor: 17.298

7.  Alpha-2A Adrenoceptor Agonist Guanfacine Restores Diuretic Efficiency in Experimental Cirrhotic Ascites: Comparison with Clonidine.

Authors:  Giovanni Sansoè; Manuela Aragno; Raffaella Mastrocola; Giulio Mengozzi; Maurizio Parola
Journal:  PLoS One       Date:  2016-07-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.